All entries for: Alnylam Pharmaceuticals, Inc.

July 30, 2026

Alnylam Pharmaceuticals, Inc.

Neutral Outlook

Cambridge, MA
1,001-5,000 employees

the effect of existing and any new healthcare laws and regulations currently being considered or implemented in the U.S. and globally, including most-favored nation pricing measures, measures requiring the U.S. government in the future to negotiate the prices of certain drugs, and price reporting and other disclosure requirements, as well as the potential impacts of such requirements on physician prescribing practices and payor coverage;

February 12, 2026

Alnylam Pharmaceuticals, Inc.

Neutral Outlook

Cambridge, MA
1,001-5,000 employees

Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties or a potential excise tax. The impact of the IRA on the pharmaceutical industry is significant and ongoing.

Disease Area: Cardiology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Biologic
Scroll to Top